Biostate AI
Detect disease years early
Houston, TX, US
Biostate AI combines RNA sequencing technology with artificial intelligence for disease diagnosis and drug response prediction. The company has invented and patented novel biomolecular technologies that perform RNA sequencing at a significantly lower cost than traditional approaches, operating as a Laboratory Developed Test (LDT) service provider.
Source: HealthTechAlpha
HealthTechAlpha provided this information. To learn more and get deep data on all digital health companies, please visit them here.
Visit HealthTechAlpha →
How We Help
Problem Statement
Traditional RNA sequencing is expensive and slow, hindering broad accessibility for disease diagnosis and drug response prediction, and research cycles are lengthy.
Core Technology
Proprietary low-cost RNA sequencing technology and AI-driven data analysis platform for disease diagnosis and drug response prediction.
Key Differentiators
Novel biomolecular technologies that perform RNA sequencing at nearly an order of magnitude lower cost than traditional approaches; AI agent that compresses research cycles from years to days (K-Dense Beta)
Clinical Focus
Disease diagnosis; Drug response prediction; Longevity
Company Info
- Business Model
- Other
- Founded
- 2024
- Total Funding
- 20,000,000
Categories
Disease Areas
Technologies
Clinical & IP
Clinical Validation
K-Dense validated with Harvard Medical School aging research; collaborations with Weill Cornell Medicine (leukemia, MS); 12+ patented technologies; 100+ academic partners
MedStartr Index Score
?What do you think of Biostate AI?
A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.